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Abstract
Background: Women living with HIV (WLWH) are at increased risk of invasive cervical cancer (ICC). International HIV
guidelines suggest cervical screening twice the first year after HIV diagnosis and thereafter annually. Adherence to
the HIV cervical screening program in Denmark is unknown.
Methods: We studied women from a population-based, nationwide HIV cohort in Denmark and a cohort of
age-matched females from the general population. Screening behaviour was assessed from 1999–2010. Adjusted odds
ratios (OR’s) for screening attendance in the two cohorts and potential predictors of attendance to guidelines were
estimated. Pathology specimens were identified from The Danish Pathology Data Bank.
Results: We followed 1143 WLWH and 17,145 controls with no prior history of ICC for 9,509 and 157,362 person-years.
The first year after HIV diagnosis 2.6% of WLWH obtained the recommended two cervical cytologies. During the
different calendar intervals throughout the study period between 29-46% of WLWH followed the HIV cervical screening
guidelines. Adjusted OR’s of attendance to the general population screening program for WLWH aged 30, 40 and
50 years, compared to controls, were 0.69 (95% CI: 0.56-0.87), 0.67 (0.55-0.80) and 0.84 (0.61-1.15). Predictors of
attendance to the HIV cervical screening program were a CD4 count > 350 cells/μL and HIV RNA < 500 copies/mL.
Calendar period after 2002 and HIV RNA < 500 copies/mL predicted attendance to the general population cervical
screening program.
Conclusions: The majority of WLWH do not follow the HIV guidelines for cervical screening. We support the idea of
cytology as part of an annual review and integration of HIV care and cervical screening in a single clinic setting.
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Background
Invasive cervical cancer (ICC) is the second most com-
mon cancer in women worldwide [1,2]. Women living
with HIV (WLWH) have an increased prevalence of
Human Papillomavirus (HPV) infection [1,3-5], which
is the main cause of ICC [1,3,6-8]. Furthermore, an in-
creased risk of progression to cervical dysplasia and ICC is
reported in WLWH compared to non-HIV-infected peers
[1,3,7-11]. As a consequence international guidelines sug-
gest an intensified screening program for ICC in WLWH
with annual visits [1]. Whereas for women living without
HIV in Denmark, screening is recommended every third
year in women aged 23–49 years and every fifth year in
women aged 50–65 years [12]. However, data on screen-
ing attendance is scarce and studies only cover short time-
spans and predominantly rely on data, where patients in
retrospect report their screening habits [13-17].
With timely and appropriate screening and treatment of
pre-invasive lesions, ICC is highly preventable [1,5,7,18,19].
The introduction of screening programs for ICC has led to
a notable decline in ICC incidence in the general popula-
tion [5,18,19], but non-attendance to screening programs
constitutes a major problem [19].
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Denmark is a unique setting to study screening behav-
iour. Due to the Danish Civil Personal Registration number
(CPR) [20] we are able to link databases with complete, na-
tionwide information ranging from data on date of birth/
death, HIV status, pathology specimens, hospital diag-
noses etc.
We aimed to examine the cervical screening coverage
in WLWH in Denmark compared to population controls
without HIV infection and to identify predictors for at-
tendance to the screening program.
Methods
Ethics statement
The study was approved by the Danish Data Protection
Agency (2010-331-0468 and 2012-331-0082) and the
Danish HIV Cohort Study (DHCS) is approved by the
Danish Data Protection Agency (2008-41-1781). Ethics
approval and individual consent are not required by
Danish legislation governing this type of study (“Act on
Research Ethics Review of Health Research Projects”,
June 14, 2001, Section 10) [21].
Setting
Denmark has a population of 5.6 million [22] and an es-
timated HIV prevalence among adults of 0.1% [23].
Medical care, including highly active antiretroviral ther-
apy (HAART), is tax-paid and provided free-of-charge to
individuals living with HIV in Denmark. Treatment of
HIV is restricted to eight specialized medical centres,
where patients are seen on an outpatient basis at intended
intervals of 12–24 weeks.
Cervical screening in Denmark
A population-based screening program for ICC was
introduced in Denmark in the mid-1960s. The Danish
National Board of Health now recommend that women
aged 23–49 years receive personal invitations for screen-
ing every third year and women aged 50–65 years every
fifth year [24]. If a cervical cytology is not received a re-
minder is sent out after 3 months and again after
6 months. Screening is free of charge and most often the
general practitioner is responsible for sample taking.
Women immigrating to Denmark get an invitation for
cervical screening as soon as they receive a personal
identification number (PIN) (see below). Danish guide-
lines do not recommend cervical screening after a total
hysterectomy for benign disease or during pregnancy, but
screening can be resumed 8–12 weeks postpartum [25].
A special cervical screening program in WLWH (HIV
screening program) has been recommended since 1995,
twice the first year after HIV diagnosis and annually
thereafter (target age group has not been specified) [1].
In this setting annual written invitations are not imple-
mented and screening relies on information from health
care professionals to WLWH. Pregnant WLWH should
have cervical cytology at their initial prenatal visit unless
a normal cervical cytology has been obtained within the
past year [1].
Registries the civil registration system
The CRS is a national registry of all Danish residents
containing information on date of birth, date of migra-
tion and date of death [20]. At birth or immigration a
10-digit PIN (CPR) is assigned to each individual, which
allows accurate linkage between population-based regis-
tries and enables treatment centres to avoid multiple
registrations of the same patient. Population controls for
this study were identified from the CRS. We used the
CPR to link data from the following registers:
Danish HIV cohort study
The DHCS is a prospective, observational, nationwide,
multicentre, population-based
cohort study of all individuals living with HIV seen at
the Danish HIV clinics since 1 January 1995. The cohort
has been described in detail elsewhere [26]. In brief, data
collection is ongoing, with continuous enrolment of both
newly diagnosed residents and immigrants with HIV. Data
is updated annually and among other variables contains:
gender, date of HIV infection, date of death and HAART
regimen. Laboratory data include CD4 counts and HIV
RNA.
The Danish Pathology Data Bank (DPDB)
The DPDB was established in 1999 and contains detailed
nationwide records of all pathology specimens analyzed
in Denmark since 1997 [27]. Data on cytology was re-
trieved using the Systemized Nomenclature of Medicine
(SNOMED) code of cervix uteri: T8×3*.
The National Patient Registry (NPR)
The NPR contains records of all inpatient hospital diag-
noses since 1977 and outpatient hospital diagnoses since
1995 [28]. To assess pregnancy we used the ICD-10 codes
O60.9 and O80.0-O84.9 for births.
The Danish Cancer Registry (DCR)
The DCR is a population-based register and contains in-
formation on all incident cancers diagnosed in Danish
citizens since 1943 [29]. Diagnoses of prior ICC were
obtained using the ICD-10 codes C53.0 - C53.9.
Study population
HIV cohort
We identified all WLWH from the DHCS with a Danish
PIN and > 16 years of age at time of HIV diagnosis. The
indexdate was defined as 1 January 1999, date of HIV
diagnosis, date of 18th birthday or date of immigration,
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whichever came last. WLWH with a history of ICC or
carcinoma in situ prior to indexdate were excluded.
Population controls
For each WLWH we identified 15 age-matched women
without known HIV from the general population in the
CRS who were alive on the patient’s indexdate. Popula-
tion controls were assigned the same indexdate as the
WLWH to whom they were matched. Only women with
no history of ICC or carcinoma in situ prior to indexdate
were included.
Statistical analyses
The study period ran from 1 January 1999 until 31
December 2010. In all analyses of screening we studied
women from age 23–65 years. To allow for a short period
of patient’s/doctor’s delay we added a grace period of
3 months to all screening intervals. Hence, the first year
after HIV diagnosis equalled 15 months after HIV diagno-
sis. Women aged 23–49 years were considered covered
by the general population screening program three years
plus a 3-month grace period after a cervical cytology and
five years plus a 3-month grace period for women aged
50–65 years. WLWH were considered covered by the
HIV screening program for one year plus a 3-month grace
period independently of age.
When studying the HIV screening program for cervical
cancer the first year after HIV diagnosis a WLWH ful-
filled screening criteria if she had obtained two cervical
cytologies within 15 months and they were at least four
months apart to reflect two screening courses. Women
infected perinatally or diagnosed with HIV before immi-
gration to Denmark were not included in this analysis.
To study screening attendance during follow-up we
evaluated the coverage for each woman at the beginning
of every calendar month in the follow-up period. Women
in the two cohorts were evaluated in four categories:
i) Controls, according to the general population screening
program; ii) WLWH, according to the general population
screening program; iii) WLWH, before HIV diagnosis,
according to the general population screening program;
iv) WLWH, according to the HIV screening program.
We estimated age specific Odds ratios (OR’s) of predic-
tors for attendance to the two screening programs at dif-
ferent ages by taking the month observed closest to age
30, 40 and 50 years (+/− 3 years) and determined whether
or not the woman was covered by the screening program.
Plots on screening attendance were produced plot-
ting screening attendance against calendar time and
age (in years), respectively. The plot representing attend-
ance plotted up against age was ragged and subsequently
smoothed.
Women were not included in the analyses during preg-
nancy (defined as 37 weeks before delivery, and 6 months
postpartum) and after hysterectomy (defined as censor-
ship from the date of surgery). Women immigrating to
Denmark had a 3-month grace period before they were in-
cluded in the screening analyses. Lastly, since pathology
data was available from 1999, we initiated the observation
of screening attendance in 2002 and 2004, to allow for a
3- and 5-year observation period before the indexdate for
women aged 23–49 and 50–65, respectively, to see if they
were covered by screening according to the general popu-
lation screening program.
The OR’s and 95% confidence intervals (CI) for predic-
tors of screening were estimated in multivariate logistic
regression analyses and adjusted for calendar period when
comparing WLWH and controls.
In the analyses of coverage of the general popula-
tion screening program and HIV screening program in
WLWH two models were computed, since CD4 count
and HIV RNA are dependent covariates and could not be
included in the same model. Route of infection, ethnicity
and calendar period were included in both models,
whereas time-updated HIV RNA was included in the first
model and replaced by CD4 count in the second model.
We only presented the OR of the CD4 count from the
second model.
Individuals with missing explanatory values were ex-
cluded from multivariate regression analyses. The validity
of the model was tested using the Hosmer and Lemeshow
Goodness-of-Fit Test.
Undetectable viral load was defined as a plasma HIV
RNA load of < 500 copies/mL, which was the highest
level of sensitivity for testing in the observation period.
Significance level was set at 0.05 (two-sided).
SAS statistical software version 9.2 (SAS Institute Inc.,
Cary, NC, USA) was used for data analysis.
Results
From the DHCS we identified 1172 WLWH fulfilling the
inclusion criteria. Of these, 29 had a prior history of ICC
or carcinoma in situ and were excluded from the analyses.
Thus leaving 1143 WLWH and 17,145 age-matched fe-
male controls in the study, representing a total of 9,509
and 157,362 person-years of follow-up. Characteristics of
the patients and controls are described in Table 1.
ICC screening according to the HIV screening program
During the first year after the HIV diagnosis, 24 (2.6%)
of 915 patients eligible for analysis obtained two cervical
cytologies (as recommended in the HIV screening pro-
gram for ICC in WLWH), while 266 (29.1%) had at least
one Pap test performed (data not shown). The proportion
of WLWH attending screening according to the HIV
screening program during the study period remained rela-
tively stable between 29-46% (Figure 1).
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ICC screening according to the general population
screening program
Attendance to cervical screening according to the general
population program increased during the study period for
both WLWH and women in the control group from 47%
to 80%, and 49% to 83%, respectively (and from 28% to
57% in the group of women observed before they were di-
agnosed with HIV infection) (Figure 1). The plot illustrat-
ing data on women observed, before they were diagnosed
with HIV infection is not shown, due to a limited number
of observations.
Age-related attendance to the general population
screening program in WLWH and controls
When comparing age-related attendance to the general
population screening program in WLWH and controls
we found that for women aged 30 years, 228 (60.2%) and
4083 (68.4%), respectively (adjusted OR 0.69, 95% CI
0.56-0.87, adjusted p = 0.0011) followed the recommen-
dations, for women aged 40 years, 377 (67.0%) and 6718
(75.0%), respectively followed the recommendations (ad-
justed OR 0.67, 95% CI 0.55-0.80, adjusted p < 0.0001),
and for women aged 50 years 164 (75.2%) and 2943
Table 1 Characteristics of women living with HIV and controls
Women living with HIV Controls
Number of individuals 1143 17,145
Follow-up (years), median (IQR) 9.4 (5.0-12.0) 10.8 (6.6-12.0)
Follow-up time, total (person-years) 9,509 157,362
Age at inclusion (years), median (IQR) 33.7 (29.0-40.1) 33.7 (29.0-40.1)
Race, n (%)





Place of HIV transmission2, n (%)
Denmark 436 (38.2) −1





Route of infection, n (%)




CD4 count at inclusion, (cells/μL),
< 200 297 (26.0) −1
200–350 288 (25.2)
> 350 476 (41.6)
Missing 82 (0.7)
Hepatitis C co-infection, n (%)
Yes 238 (20.8) −1
No 905 (79.2)
AIDS at inclusion, n (%)
Yes 33 (2.9) −1
No 1110 (97.1)
1No information available, 2Self-reported geographic location at the time of HIV acquisition.
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(78.7%), respectively followed the recommendations (ad-
justed OR 0.84, 95% CI 0.61-1.15, adjusted p = 0.28)
(data on OR’s not shown) (Figure 2).
Predictors of attendance to the HIV screening program
Predictors of attendance to the HIV screening program in
the adjusted analyses in the three age groups were:
30 years: HIV RNA < 500 copies/mL and CD4 count > 200
cells/μL; 40 years: HIV RNA < 500 copies/mL; 50 years:
CD4 count > 350 cells/μL as opposed to a CD4 count be-
tween 200–350 cells/μL. HIV RNA < 500 copies/mL and a
CD4 count > 350 cells/μL were predictors for attendance
in all age groups in the unadjusted analyses (Table 2).
Predictors of attendance to the general population
screening program
Attendance of WLWH to the general population screening
program improved after year 2002 for women age 30 and
40 years (adjusted OR 1.77, 95% CI 1.04-3.02 and adjusted
OR 3.45, 95% CI 2.05-5.78). Additionally, HIV RNA< 500
copies/mL was a predictor for attendance (Table 2). In the
unadjusted analyses predictors of attendance in the three
age groups were: 30 years: Calendar period after 2002 and
HIV RNA< 500 copies/mL; 40 years: Heterosexual route
of infection, calendar period after 2002, HIV RNA < 500
copies/mL and CD4 count > 350 cells/μL; 50 years: HIV
RNA < 500 copies/mL (Table 3).
In all adjusted analyses we performed sensitivity ana-
lyses to check for the effect of missing values on out-
come by adding an extra category with missing values.
However, this had no impact on the estimates.
Discussion
We found that between 29-46% of WLWH followed the
recommended HIV cervical screening program during
the study period. Moreover, WLWH displayed lower at-
tendance to the less demanding general population
screening program for ICC than controls. Screening at-
tendance to the general population screening program
improved gradually after 2002, but not according to the
HIV screening program and a predictor of attendance to
both guidelines was HIV RNA < 500 copies/mL. Lastly, a
CD4 count > 350 cells/μL predicted attendance to the
HIV screening program.
Attendance to the HIV cervical screening program the
first year after HIV diagnosis was remarkably low with
only 2.6% of WLWH attending the two recommended











01/2002 07/2002 01/2003 07/2003 01/2004 07/2004 01/2005 07/2005 01/2006 07/2006 01/2007 07/2007 01/2008 07/2008 01/2009 07/2009 01/2010 07/2010 01/2011
GROUP: Controls, GP guidelines HIV+, GP guidelines HIV+, HIV guidelines
Figure 1 The proportion of women attending the cervical cancer screening program during the observation period. Women living with
HIV (WLWH) and controls are divided into three categories: i) Controls, studied according to the general population (GP) screening program;
ii) WLWH, studied according to the GP screening program; iii) WLWH, studied according to the HIV screening program. Since no data is available
before 1999 the curve has been started in 2002 to allow for three years of observation.
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after HIV diagnosis focus is on other urgent physical
and mental health issues.
We report a cervical screening coverage between 60%
and 75% depending on age in WLWH according to the
general population screening program and a screening
coverage during the study period on only about a third
to a half of all WLWH according to the HIV cervical
screening program. The screening coverage found in the
present study is considerably lower than what have been
published in previous studies reporting a coverage to the
annual ICC HIV screening program between 51% and 81%
[13,14,16,30]. These studies are based on self-reported
data, and the difference might reflect that women tend to
over-report their participation in cervical screening in a
given timeframe and therefore these rates are likely upper-
end estimates [31]. Furthermore, unlike register-based
studies, to participate in studies based on self-reported
data, women being recruited have to attend care for HIV
infection else they are excluded a priori. In line with this,
data concerning the general population suggest that
women are less likely to have received a cervical cytology
when they have no contact to primary care [32]. The Swiss
HIV Cohort Study found a self-reported semi-annual
coverage of 35% [17], but studies are hard to compare due
to the study design with semi-annual questionnaires.
Two register-based studies from New Zealand and the
UK both found a relatively high coverage of cervical
screening of 68% and 74%, respectively, within the previ-
ous 12 months [33,34]. However, in New Zealand the
annual review for WLWH included the option of having
cervical cytology performed at the sexual health clinic
when attending for HIV-related care. A small Australian
audit found a screening coverage comparable to the
present study of only 27% the previous year [15], which
the authors among others ascribe cultural reticence in
immigrants and lack of health knowledge. In a postnatal
cohort from Ukraine 30% of women had a cervical cy-
tology performed in the past, though only tests taken as
a part of HIV care were registered [7].
In the present study both WLWH and controls were
more likely to take up cervical screening according to the
general population screening program after 2002, prob-
ably owing to more focus on cancer screening programs
per se in the Danish society. This did however not trans-
late into increased screening attendance in WLWH ac-
cording to the HIV cervical screening program.
In line with Shah et al. [35] we found that an HIV
RNA < 500 copies/mL as a proxy for being on HAART
and therefore attending the HIV clinics for regular con-













20 30 40 50 60 70
GROUP: Controls, GP guidelines HIV+, GP guidelines HIV+, HIV guidelines
Figure 2 The proportion of women attending the cervical cancer screening program distributed by age divided into three categories:
i) Controls, studied according to the general population (GP) screening program; ii) women living with HIV (WLWH), studied according
to the GP screening program; iii) WLWH, studied according to the HIV screening program.
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Table 2 Predictors of attendance to the HIV cervical cancer screening program in WLWH1 aged 30, 40 and 50 years
Predictors of attendance
in different age groups
30 years (n = 386) 40 years (n = 555) 50 years (n = 214)
n (%) attending
screening
Unadjusted Adjusted n (%) attending
screening




Heterosexual contact 124 (45.4) 1.00‡ 1.00‡ 177 (45.9) 1.00‡ 1.00‡ 72 (50.0) 1.00‡ 1.00‡
Intravenous drug use 11 (44.0) 0.94 (0.41-2.15) 0.77 (0.31-1.92) 19 (35.2) 0.64 (0.35-1.16) 0.64 (0.33-1.23) 10 (43.5) 0.77 (0.32-1.87) 0.91 (0.34-2.45)
Other 2 (33.3) 0.60 (0.11-3.35) 0.48 (0.08-2.77) 4 (33.3) 0.59 (0.18-1.99) 0.52 (0.15-1.78) 2 (66.7) 2.00 (0.18-22.55) 1.93 (0.16-22.57)
(missing) (82) (103) (44)
Race,
White 51 (48.6) 1.00‡ 1.00‡ 95 (47.7) 1.00‡ 1.00‡ 46 (46.5) 1.00‡ 1.00‡
Asian 22 (38.6) 0.67 (0.35-1.28) 0.51 (0.25-1.07) 24 (48.0) 0.99 (0.53-1.84) 0.93 (0.48-1.80) 7 (58.3) 1.61 (0.48-5.43) 1.66 (0.42-6.57)
Black 65 (43.9) 0.83 (0.50-1.37) 0.75 (0.43-1.32) 87 (42.2) 1.25 (0.84-1.85) 0.72 (0.47-1.12) 29 (50.0) 1.15 (0.60-2.20) 0.90 (0.43-1.86)
Other 4 (57.1) 1.41 (0.30-6.62) 1.22 (0.25-5.96) 5 (31.3) 2.01 (0.67-5.99) 0.49 (0.14-1.64) 3 (60.0) 1.73 (0.28-10.80) 0.87 (0.11-6.57)
(missing) (69) (84) (40)
Calendar period
01.01.2002 – 31.12.20022 47 (37.0) 1.00‡ 1.00‡ 35 1.00‡ 1.00‡ 5 (55.6) 1.00‡ 1.00‡
01.01.2003 – 31.12.2010 99 (38.2) 1.05 (0.68-1.63) 0.97 (0.59-1.62) (35.0)176 (38.7) 1.17 (0.75-1.84) 1.00 (0.59-1.67) 81 (39.5) 0.52 (0.14-2.00) 0.39 (0.07-2.11)
Time-updated HIV
RNA (copies/mL)
>500 48 (27.8) 1.00† 1.00† 43 (26.9) 1.00† 1.00† 12 (26.1) 1.00† 1.00‡
<500 96 (47.3) 2.34 (1.52-3.60) 2.06 (1.27-3.33) 165 (43.2) 2.07 (1.38-3.10) 1.87 (1.18-2.97) 73 (45.6) 2.38 (1.15-4.92) 2.21 (0.98-4.99)
(missing) (10) (13) (8)
Time-updated CD4
count (cells/μL)
< 200 11 (19.3) 1.00† 1.00† 16 (23.9) 1.00† 1.00‡ 6 (25.0) 1.00† 1.00†
200–350 31 (36.9) 2.45 (1.11-5.41) 2.48 (1.06-5.76) 34 (32.4) 1.53 (0.76-3.06) 1.17 (0.55-2.49) 8 (24.2) 0.96 (0.28-3.25) 0.61 (0.16-2.42)
> 350 102 (43.2) 3.18 (1.57-6.45) 3.02 (1.42-6.42) 159 (42.9) 2.39 (1.32-4.35) 1.58 (0.82-3.05) 71 (47.3) 2.69 (1.01-7.17) 2.41 (0.79-7.33)
(missing) (9) (12) (7)
Unadjusted and adjusted odds ratios (OR’s) for predictors of attendance. Predictors of attendance to the cervical screening program in different age groups were estimated including the month observed closest to 30,
40 and 50 years (+/− 3 years) to determine whether or not the woman was covered by screening. Two models are shown in the table: Mode of transmission, ethnicity and calendar period were included in both
models, whereas time-updated HIV RNA was included in the first model and replaced by CD4 count in the second model. We only presented the OR of the CD4 count from the second model. 1Women living with HIV
(WLWH). 2Since no data was available before 1999 the reference period only included 2002 to allow for three years observation before initiation.



















Table 3 Predictors of attendance to the general population cervical cancer screening program in WLWH1 aged 30, 40 and 50 years
Predictors of attendance
in different age groups
30 years (n = 379) 40 years (n = 563) 50 years (n = 218)
n (%) attending
screening
Unadjusted Adjusted n (%) attending
screening




Heterosexual contact 197 (70.1) 1.00‡ 1.00‡ 315 (78.6) 1.00† 1.00‡ 132 (89.2) 1.00‡ 1.00‡
Intravenous drug use 15 (60.0) 0.64 (0.28-1.48) 0.53 (0.21-1.35) 36 (63.2) 0.47 (0.26-0.84) 0.70 (0.35-1.38) 23 (82.1) 0.56 (0.19-1.67) 0.74 (0.22-2.46)
Other 4 (57.1) 0.57 (0.13-2.60) 0.42 (0.09-2.02) 8 (66.7) 0.55 (0.16-1.86) 0.37 (0.11-1.32) 3 (100) -2 -2
(missing) (66) (93) (0)
Race,
White 76 (71.0) 1.00‡ 1.00‡ 154 (73.7) 1.00‡ 1.00‡ 89 (84.8) 1.00‡ 1.00‡
Asian 36 (62.1) 0.67 (0.34-1.31) 0.45 (0.21-0.98) 42 (80.8) 1.50 (0.71-3.19) 1.14 (0.51-2.60) 12 (92.3) 2.16 (0.26-17.76) 1.66 (0.19-14.77)
Black 106 (68.8) 0.90 (0.53-1.54) 0.72 (0.38-1.34) 170 (79.8) 1.41 (0.90-2.23) 1.29 (0.77-2.18) 56 (93.3) 2.52 (0.80-7.91) 1.81 (0.52-6.26)
Other 6 (85.7) 2.45 (0.28-21.17) 1.98 (0.22-17.68) 11 (68.8) 0.79 (0.26-2.36) 1.14 (0.32-4.11) 6 (100) -1 -2
(missing) (53) (73) (34)
Calendar period
01.01.2002 – 31.12.20023 65 (51.2) 1.00† 1.00† 48 (46.6) 1.00† 1.00† 8 (72.7) 1.00‡ 1.00‡
01.01.2003 – 31.12.2010 163 (64.7) 1.75 (1.13-2.69) 1.77 (1.04-3.02) 329 (71.5) 2.88 (1.86-4.45) 3.45 (2.05-5.78) 156 (75.4) 1.15 (0.29-4.49) 1.04 (0.12-9.33)
Time-updated HIV
RNA (copies/mL)
> 500 86 (52.8) 1.00† 1.00‡ 90 (54.2) 1.00† 1.00† 29 (60.4) 1.00† 1.00‡
< 500 137 (66.8) 1.80 (1.18-2.75) 1.37 (0.83-2.28) 279 (73.0) 2.29 (1.57-3.34) 1.76 (1.08-2.88) 130 (79.8) 2.58 (1.29-5.16) 2.43 (0.88-6.71)
(missing) (11) (15) (7)
Time-updated CD4
count (cells/μL)
< 200 33 (56.9) 1.00‡ 1.00‡ 40 (56.3) 1.00† 1.00‡ 14 (58.3) 1.00‡ 1.00‡
200–350 42 (52.5) 0.84 (0.42-1.65) 0.49 (0.21-1.13) 61 (58.7) 1.10 (0.60-2.02) 0.67 (0.30-1.51) 24 (70.6) 1.71 (0.57-5.13) 1.54 (0.36-6.53)
> 350 147 (63.9) 1.34 (0.75-2.41) 0.76 (0.36-1.61) 269 (71.9) 2.00 (1.18-3.34) 1.07 (0.52-2.19) 121 (79.1) 2.70 (1.10-6.64) 4.33 (1.24-15.10)
(missing) (11) (14) (7)
Unadjusted and adjusted odds ratios (OR’s) for predictors of attendance. Predictors of attendance to the general population cervical screening program in different age groups were estimated including the month
observed closest to 30, 40 and 50 years (+/− 3 years) to determine whether or not the woman was covered by screening. Two models are shown in the table: Mode of transmission, ethnicity and calendar period were
included in both models, whereas time-updated HIV RNA was included in the first model and replaced by CD4 count in the second model. We only presented the OR of the CD4 count from the second model,
1Women living with HIV (WLWH), 2Could not be estimated, due to shortage of events, 3Since no data was available before 1999 the reference period only included 2002 to allow for three years observation
before initiation.



















screening attendance. This difference was only found to
be statistically significant at age 40 years. As previously
reported [13,30] attendance to the HIV screening pro-
gram was predicted by a high CD4 count (> 350 cells/μL),
which we again see as a proxy for being well-treated for
one’s HIV infection. This causes further disparity, since
women with low CD4 counts reportedly are at higher risk
of ICC [3,16].
Predictors of attendance to screening programs in
other studies were a diagnosis of HIV prior to pregnancy
[7], previous pregnancies [7], history of abnormal cervical
cytology [30], heterosexual transmission [35], screening
advice from a gynaecologist rather than an infectious
medicine specialist [30], older age [35], Black ethnicity
[35] and integration of HIV care and ICC screening in the
same setting [14].
In Denmark, the annual screening of WLWH is pre-
dominantly performed at the general practitioners. Con-
tributing to the low coverage of cervical screening in
WLWH most notably seen the first year after HIV diag-
nosis could be a combination of lack of knowledge and
information from the health care professionals at the
HIV centres to WLWH and lack of knowledge among
general practitioners on the intensified HIV screening
program for WLWH.
Only about a half of WLWH followed the general
population screening program before HIV diagnosis. This
screening behaviour is hard to interpret, since the group
of WLWH followed before HIV diagnosis is smaller, time
of follow-up varies and women immigrating to Denmark
with HIV cannot be surveyed. Yet, we speculate whether
this group of women generally practice less self-care than
women in the general population.
Screening attendance for women in the general popula-
tion was 83% in the end of the study period, which is a bit
higher than the 3-year coverage reported for the entire eli-
gible population of Denmark about 76% in 2010 [36].
The major strength of our study is the nationwide
population-based design, linking the nationwide registers
DHCS, CRS and DPDB, with very limited loss to follow-
up [37], which ensures that data is not subject to recall
bias. Moreover, our ability to integrate data on pregnancy,
immigration, hysterectomy and prior ICC into the ana-
lyses optimizes accuracy of results.
Some limitations need to be considered: Baseline infor-
mation on WLWH was those reported by the providers
and then retrospectively summarized for this study. Add-
itionally, we have not assessed dysplasia. A woman with a
history of dysplasia might for a period due to gynaeco-
logical treatment and guidelines attend cervical screen-
ing more often and if rates of dysplasia are increased in
WLWH in Denmark as seen in foreign cohorts [1,3,7-11],
we might tend to overestimate adherence to the cervical
screening program amongst WLWH.
We chose to evaluate adherence to the screening pro-
gram on a monthly basis for all women during the study
period. We did this to analyse the dependency on co-
variables at specific arbitrarily chosen ages in order to
have a single, easily defined, endpoint for each woman
that could also reflect the development over age for the
predictors in the model. Using this mode of analysis, we
could model the times of cytology directly and allow for
estimates that reflects coverage. The analysis was chosen
over a more dynamic model that would rather reflect
delay in screening behaviour than coverage. However,
the chosen analysis does not provide the possibility of
estimates of age as a predictor and represents a reduction
of data. Finally, ethnicity of controls was not assessed in
the analyses. We are far from complying with cervical
screening guidelines for WLWH. Still, incidence of
cervical dysplasia in WLWH in Denmark is unknown.
However, if rates of dysplasia are high as reported from
other cohorts [1,3,7-11], this yields for new approaches to
cervical screening in WLWH. We support the idea of cy-
tology as part of an annual review [15,33] and integration
of HIV care and cervical screening in a single clinic setting
[14,35,38]. Another measure-inspired by Australian health
authorities [15] – could be an opt in automated reminder
system with written invitations to women with overdue
cervical cytologies. Moreover, targeted public health mes-
sages aimed at health care professionals at HIV centres,
general practitioners and WLWH are essential.
Conclusion
The majority of WLWH do not follow the recom-
mended HIV screening program for ICC and they display
lower attendance to the general population screening pro-
gram than controls. This yields for new approaches to in-
crease attendance to cervical screening in WLWH, since
low ICC screening attendance may lead to overrepresenta-
tion of cervical dysplasia and ICC in WLWH in Denmark.
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